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Abstract
Background: Translational research requires taking basic science observations and developing
them into clinically useful tests and therapeutics. We have developed a process to develop
molecular biomarkers for diagnosis and prognosis by integrating tissue microarray (TMA)
technology and an internet-database tool, Profiler. TMA technology allows investigators to study
hundreds of patient samples on a single glass slide resulting in the conservation of tissue and the
reduction in inter-experimental variability. The Profiler system allows investigator to reliably track,
store, and evaluate TMA experiments. Here within we describe the process that has evolved
through an empirical basis over the past 5 years at two academic institutions.
Results: The generic design of this system makes it compatible with multiple organ system (e.g.,
prostate, breast, lung, renal, and hematopoietic system,). Studies and folders are restricted to
authorized users as required. Over the past 5 years, investigators at 2 academic institutions have
scanned 656 TMA experiments and collected 63,311 digital images of these tissue samples. 68
pathologists from 12 major user groups have accessed the system. Two groups directly link clinical
data from over 500 patients for immediate access and the remaining groups choose to maintain
clinical and pathology data on separate systems. Profiler currently has 170 K data points such as
staining intensity, tumor grade, and nuclear size. Due to the relational database structure, analysis
can be easily performed on single or multiple TMA experimental results. The TMA module of
Profiler can maintain images acquired from multiple systems.
Conclusion: We have developed a robust process to develop molecular biomarkers using TMA
technology and an internet-based database system to track all steps of this process. This system is
extendable to other types of molecular data as separate modules and is freely available to academic
institutions for licensing.
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Taking laboratory discoveries and translating them into
clinically useful diagnostic tests or targeted therapies
requires the use of human samples for validation. This
process, referred to as translational research, requires care-
fully storing and maintaining detailed annotation of these
samples. Tissue Microarray (TMA) technology has created
and efficient manner to accelerate discovery but has also
created a new demand for databases to handle a large
number of data points in a regulatory compliant manner.
The initial description of Tissue Microarray (TMA) tech-
nology by Kononen et al. [1] began a revolutionary
change in the way that many tissue based research studies
would be performed. TMA technology allows for the pre-
cise placement of typically up to 400–800 tissue samples
into a single block in an array. The approach some major
advantages as compared to using standard slides. TMA
technology decreases experimental variability, conserves
tissue resources and provide a dramatic cost benefit once
the initial TMA block is constructed [2].
TMA technology also presents some challenges, which
include issues related to sampling strategies [3-5], evalua-
tion of TMA samples[6,7], ability to store and maintain
the data derived from TMA experiments [8-11], and anal-
ysis of TMA datasets [12]. All of these issues are important
to understanding the utility of TMA technology and to
help maximize its potential as a research tool. In the col-
laborative setting of the Specialized Program of Research
Excellence (S.P.O.R.E.) for Prostate Cancer, a program for
translational research, pathologists from the University of
Michigan, Baylor School of Medicine, and Johns Hopkins
developed a working model to deal with these challenges.
We recognized some fundamental guiding principles: (1)
TMA technology provides a means to conserve finite tissue
resources, while at the same time increasing the number
of studies for qualified investigators; (2) TMA technology
is most valuable if data generated from each experiment is
recorded and returned to a central database thus increas-
ing the annotation and value of each sample; and (3) TMA
technology is ideally suited for collaborative biomarker
research. These important guidelines suggested to our
working group that TMA databasing tools would be a cor-
nerstone to our translational research activities and would
grow in importance over time and with the increasing
number of experimental data.
In 2001, we described the blueprints for developing a
means of storing, maintaining and evaluating TMA data
using Internet tools and a relational database [6,10]. From
this original work has emerged an integrative framework
for dealing with all aspects of TMA research (Figure 1). At
the center of this process is an internet-based database sys-
tem referred to as Profiler. This system has the capability
of handling/managing a wide variety of sample types
from different disease states (i.e., prostate, breast, lung,
renal, skin, etc.) and because of its modular design can
also store and maintain other types of molecular data
including expression array data, karyotype data, and SNP
array data. Here within, we describe the process that has
developed to deal with TMA experiments and the Profiler
system used to manage the data associated with these
experiments.
Results
Over the past 5 years, the Profiler system has developed
into a key ingredient into the process for TMA based
research. The data included in this process not only
includes the alpha-numeric annotations to each histospot
but also the images that are associated with each study.
The Profiler system has demonstrated a capacity to be
extendable to other organ sites besides prostate and mod-
ular allowing for analysis of other types of molecular data.
To date multiple studies were built/conducted using this
system [2,4-6,13-29]. The following is a description of the
process that has developed over years of TMA research
(Figure 1).
TMA conceptual research design
TMA design is crucial because it should address the needs
of future experiments (Figure 1b, top). Once the TMA
design is thought out, two different types of maps are cre-
ated to assist in the TMA fabrication, a picture map (Figure
1b, lower) and a punching map (not shown). The picture
map is a visual representation of the TMA showing a lay
out of all the TMA cores. Different tissue types or diag-
noses can be shown in colors. The picture map provides
orientation. The punching map is needed for taking
biopsy cores with the manual arrayer. This map shows the
x and y localization of each TMA core and is used during
the construction of the TMA.
The physical configuration of the TMA is entered into the
Profiler database. All future studies (see below) will main-
tain this structure and use the information from the
punch file to help determine: 1) the type of tissue; 2) tar-
geted diagnosis; 3) the x and y coordinates (i.e., location);
and 4) associated research identification code for poten-
tial links to clinical and pathology data from external or
internal databases.
Experiments
Each antibody is evaluated using a small test TMA. A test
TMA consists of an assortment of different tissues to test
the best experimental protocols including pre-treatments
and dilutions. The test TMAs are then reviewed by a
pathologist and the TMA experiment will then be per-
formed using these optimal conditions (Figure 1c, lower).
This process prevents wasting valuable large TMAs.Page 2 of 11
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a-e. Profiler System Organization and Workflow for TMA Module. Component view of the architecture of the Profiler frame-
work(a). The Profiler interfaces with multiple components besides TMA data. For example, the Clinical Research Information 
System (CRIS) component manages clinical data on patients being taking care of at the Dana Farber Cancer Institute and the 
Brigham and Women's Hospital. Using regulatory compliant protocols, appropriate consented cases information can be linked 
to the system. The karyotype component manages cytogenetic data. Different components are linked by means of unique iden-
tifiers (e.g., research coded identifier). The current system contains modules for karyotype, expression array, SNP array (not 
shown), and tissue microarray (TMA) data. Users can access different components using Graphical User Interfaces (GUI) at 
local workstations. The process of TMA use can for research can be divided into 5 steps, which include the following: research 
design, experiments, scanning of histospot images, histospot evaluation, and analysis. The profiler system is designed to store 
data for all 5 steps of this process. The first step in the work flow of a TMA study is the research design (b). As described in the 
text, each TMA study design is based on the questions being addressed. Three examples are given in this schematic view of 
research design. Test TMAs are usually small TMA with a small number (i.e., n = 100) cores. The test arrays are useful for 
working up reagents. These arrays provided limited information regarding protein expression or RNA expression and repre-
sent an efficient method of conserving tissues. Survey TMAs allow for determination of expression on a wide range of samples. 
Standard survey TMAs have approximately 500 histospots. An outcomes TMA may include a large number of samples with 
outcomes information. These usually represent the most valuable samples given the annotation of each case. As described in 
the results section, organization of the paraffin tissue blocks (upper right), circling of the areas of interest on standard slides 
and construction of the TMA are the final steps of developing a TMA for experiments. After the conceptual design of the TMA 
experiment, a physical map (TMA Map, bottom) is draw based on the available tissue blocks. The research identifiers from 
these blocks are linked to the research patient identifiers. Part of the experiment includes the construction of TMA (e, top). 
Glass slides and blocks are organized, the pathologist circles the areas of interest and tissue cores are taken from the donor 
block and placed into a tissue microarray. Typical types of experiments that can be performed using TMAs include immunohis-
tochemistry (IHC), immunofluorescence (IF), in situ hybridization (ISH), and Fluorescence In Situ Hybridization (FISH) (c, bot-
tom). Following experiments with IHC, histospot are scanned (not shown) and the data is evaluated using the Internet 
interface of Profiler (d). As described in the text, the system allow the reviewer to view the histospot images at several magni-
fications (shown is 10 ×, also available are 2.5 ×, 5 ×, and 20 × magnification). Data can be added by the reviewer (d, right side). 
The reviewer can also see the TMA map design (d, bottom). The growing annotated data on a TMA makes it more valuable 
over time. Analysis is performed on the data usually outside of the Profiler system using standard statistical analysis tools (e). 
Type of results that can be evaluated using TMA technology include the evaluation of individual biomarkers with respect to 
clinical outcomes as represented by a survival curve (e, left) or global protein expression as represented by a heat map from 
multiple TMA experiments (e, right).Scanning
As described in the methods section, the TMA is scanned
and the images are entered into the Profiler database
server for evaluation. Initially all slides were scanned with
the Bliss system. However, more experiments are being
performed using the other imaging systems (described in
the methods section).
Study set up
At an administrative level, the research group determines
who should be permitted access to evaluate the TMA.
Using Profiler study set up tools, the administrator is
given a set of options for the reviewer to have available at
time of review. For example, in some studies, staining
intensity and percentage intensity are the only parameters
that need to be annotated. In another study, nuclear grade
may be required. These types of decisions are based on the
goals of the study. Once the study is set up, the reviewers
are sent a unique user password for them to gain access to
studies they are responsible for reviewing. The advantage
of this approach is flexibility. As we have seen over the
past 5 years, each research group needs to enter data fields
that are not readily generalizable to all other groups nor
are they relevant. As a specific example, tumor grading sys-
tems are often organ specific (e.g., Gleason grading, Fuhr-
man Grading, etc). Therefore flexibility is critical to allow
each group to be able to enter relevant data for their stud-
ies. One major disadvantage is that we do not anticipate
being able to develop a "standard" set of look up tables to
cover every research groups needs and therefore a pro-
grammer will be needed to make modifications to the sys-
tem until it meets an individual groups needs.
TMA evaluation
Each user gains access to a TMA slide based on their exper-
iments. The reviewer can only see their own folders and
not those from other research groups. These safety fea-
tures are part of the Oracle security tools that are required
for e-commerce. As the user views each TMA core image,
information about the TMA core is displayed in the region
of the screen adjacent to the diagnostic parameters (Figure
1d). The TMA core's X and Y coordinates are displayed
with its organ type and target diagnosis. The diagnostic
parameters are inputted along with stain intensity, stain-
ing location, and path diagnosis using pull down menus.
Comments can be entered in a separate free text field.Page 4 of 11
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finalize the evaluation preventing any further changes in
the diagnostic parameters. The study design is flexible dif-
fering dramatically based on the research group. Clinical
and pathology information can be either presented or not.
For example, the TMA map is usually available (Figure 1d,
lower right). However, one could imagine a study where
the investigators may know the design of the TMA and
therefore would be biased if this information were availa-
ble at time of review. We have also found that the tissue
diagnosis of each histospot is critical during the evalua-
tion process. When drilling deeper into a block, TMA sam-
ples may demonstrate different tissue types (i.e., cancer
versus benign) due to tumor heterogeneity.
Data storage
After each TMA core is reviewed and diagnostic parame-
ters are inputted, the user will submit the information and
the next TMA core image will be displayed with all the
diagnostic parameters reset for another submission (Fig-
ure 1a). The diagnostic data is uploaded onto the data
server.
Analysis
The methods used to analyze TMAs are beyond the scope
of this current study. However, it is important to point out
that, once a TMA slide has been finalized, all of the raw
data is maintained on the Profiler system and available for
analysis. The data and images can be queried based on
desired features such as all tumor samples staining posi-
tive for biomarkers x, y, and z. This feature recalls previous
evaluations from the server based on specified parameters
(specific cases, tissue cores with particular diagnoses,
immunohistochemistry, etc) and displays the data and
the corresponding image showing multiple evaluations of
one patient adjacent to one another. Query results and
single experiment data can be exported as an excel spread-
sheet or as a tab delimited text file for further statistical
analysis. The system is capable of displaying uploaded
data from automated immunostaining results from the
Chromavision System, so as all the data stored in the data-
base being related to a specific dataset of interest.
Additional resources
The Profiler System can be setup to assist in submitted
publications as supplementary data showing all informa-
tion about the study giving raw data as well as the images
of the TMA slides. This was recently done with the publi-
cation of a biomarker study called Jagged1[30].
Profiler usage
The Profiler system is currently running at Dana Farber
Harvard Comprehensive Cancer and the University of
Michigan Comprehensive Cancer Center containing 73.5
K and 95.3 K data points, respectively. 656 TMA slides
have been scanned and 63 K histospots evaluated by 68
pathologists. Of the TMAs evaluated, 12 major user
groups use the systems including 8 S.P.O.R.E. groups with
two groups having directly linked clinical data containing
over 500 patients giving immediate access.
Availability and requirements
One can register for a standard non-anonymous demon-
stration[31]. This demonstration provides the user with
some but not all of the features of the database. The sys-
tem is accessible via the Internet and currently works on
PC computers using Internet Explorer.
Discussion
In the current study, we describe the evolution of a process
that has developed over the past 5 years to use TMAs for
biomarker studies. At the center of this process is a rela-
tional database tool, Profiler, which allows users to han-
dle all steps of TMA research (Figure 1). The profiler
system was originally developed for work in the field of
prostate cancer biomarker research but has now been
expanded to allow for the analysis of any tissue type. This
system has been extensively used by investigators from
several academic institutions.
The key feature to Profiler's functionality is the ability to
access TMA images over the Internet and enter data in a
secure manner. During the course of our first TMA experi-
ments, we observed that there was a high probability of
annotating the wrong TMA histospot when multiple
pathology reviewers were involved due to density of these
TMAs, which typically have 500 TMA cores. We therefore
developed a system to present TMA images to the reviewer
thus avoiding having to physically identify the TMA hist-
ospot by examining the slide. Manually evaluating a TMA
slide under the microscope can be a common source of
error, since it is reasonably easy to loose track of which
samples have been evaluated. Profiler keeps track of
which cores have been reviewed so the entire TMAs can be
analyzed over a single session or multiple sessions.
The integration of TMA data with other data sets is critical
for the development of biomarkers. In version 3.0 of Pro-
filer, other databases can be loaded securely onto the sys-
tem. Over the past 5 years, several groups with rich clinical
and pathology data have used the system to evaluate
molecular biomarkers. Profiler's database keeps different
datasets separate from each other, maintaining private
space for research groups to develop projects. This has
become an important issue with some cooperative groups
that need to maintain control over their clinical databases
based on pre-existing sharing agreements.
Worldwide, one of the guiding principles for any database
that maintains clinical data is compliance with local regu-Page 5 of 11
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United States, HIPPA regulations guide how clinical data-
bases can be integrated with the data stored in Profiler. We
have developed two approaches. The first approach is to
maintain both datasets separately and then the integra-
tion of the Profiler TMA data is performed by the clinical
group. They are then typically able to provide a com-
pletely integrated dataset without any patient identifiers.
This dataset is now ready for analysis. The second
approach is to integrate the clinical data into the Profiler
system as a separate clinical module. We have done this
for several groups and have used Oracle security and
administrative tools to ensure that the clinical module is
only available for viewing and modifying by the desig-
nated clinical groups researchers. All queries require the
group leader's approval and each time a query is per-
formed on the clinical data, the time, date, and investiga-
tor are recorded and send via email to the group leaders.
This monitoring feature is critical to ensure that the clini-
cal database is only used by qualified investigators. The
system administrator assigns users different levels of
access at different sites using password protected user pro-
files.
The tracking of standard operating procedures (SOP) is
critical for the interpretation of experimental results over
time. Therefore the development of a "laboratory book"
feature as a new module is critical to the adequate anno-
tation of samples and experiments. We are currently
developing the ability to input experiment related data
such that a laboratory technician could annotate the stain-
ing protocol of each experiment (timing, dilutions, etc).
In addition, acquisition settings and image analysis proce-
dures will also be stored in this module of Profiler. Vali-
dation studies require specific protocols to reproduce all
of the experimental conditions, this module should
ensure that this data is available.
Few papers have been published so far on TMA data
organization and management. Liu et al. [9] presented a
system for high-throughput analysis and storage of TMA
immuno-staining data, using a combination of commer-
cially available software and novel software. Similarly,
Shaknovich et al. [32] proposed a way to manipulate TMA
data and images, using commercially available software.
Other academic groups are working on the development
of systems integrating commercially available software for
the acquisition of digital images and the automatic evalu-
ation of markers with custom solutions for data organiza-
tion and management.
The Johns Hopkins Tissue Microarray Laboratory has also
developed a set of software tools and underlying database
structure to manage TMA data[33]. It allows the storage of
a wide variety of information related to TMA samples,
including patient clinical data, specimens, donor blocks,
core, and recipient block information. A dynamic data-
base structure allows users to add custom fields for differ-
ent organ systems. The client application facilitates
automated and manual entry of data related to patients,
specimens, tissue blocks, and tissue sub-blocks (individ-
ual pathological diagnoses). The system allows users to
design their own block arrays. Digital images generated by
the Bacus Labs Inc. Slide Scanner (Bacus laboratories,
Lombard, IL,) [34] are imported into the database and
available for on line visualization and evaluation.
Although this system developed separately from the Pro-
filer system, the two groups worked closely initially as part
of the S.P.O.R.E. initiative to develop TMAtechnology for
translational research[10].
Some other systems have been developed to automati-
cally acquire and evaluate TMA samples, such as the
TMALab ™ (Aperio technology) [35], or the Pathfinder™
Morphoscan™ [36]. These solutions work well with high
quality TMA slides, usually by superimposing a grid on
the panoramic overview of the slide, but they require con-
siderable manual intervention if the TMA samples are not
well aligned. These systems are similar to the Bliss and
Chromavision systems in that none of these systems iden-
tify the histospots automatically. The misalignment of
TMA histospots is inevitable due to the way the samples
are processed. After a thin 4–5 micron thick section is cut,
the histotechnologist floats the sample in a water bath.
Even when done by the best-trained technologists, there is
slight movement of the samples. Therefore using a grid
will never be a practical solution to automate the identifi-
cation of the samples.
The AQUA system uses an object recognition approach to
exactly identify the spatial coordinate of each spot, but
lacks in ordering and assigning them to proper patient
and/or clinical information based on construction infor-
mation[7].
The Bioinfomatics Group of ITC in Trento, Italy, has
developed an integrated framework for the management
of TMA experiment data [37]. This system called TMA-
Boost is a patient centered web based system. It integrates
a custom made TMA digital environment for the auto-
matic localization, identification, acquisition and evalua-
tion of TMA single spot. One unique feature of this system
is the ability to recognize the histospots taking the TMA
map into account [38]. A probability is determined as to
the likelihood that a specific histospot is being correctly
identified based on the physical map of the TMA. This fea-
ture is particularly useful, as during the course of prepar-
ing a slide for immunohistochemisty, some histospots
may be lost. Ambiguously located histospots would thenPage 6 of 11
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using the existing data reduces the chance that TMA hist-
ospots are pared with the incorrect x-y coordinate.
Another important feature of TMA based studies is the
growing need to share data and information among dif-
ferent institutions (e.g., multi-center studies, clinical tri-
als, etc.). In such a setting, the implementation of
standard data exchange protocols becomes critical as up
to now there have not been standard approaches to col-
lecting data at different institutions and sometimes even
within the same institution and as centralized solutions
are not feasible. As a result of several TMA workshops in
the area of TMA bioinformatics, TMA Exchange Specifica-
tions have been released that allow TMA data to be organ-
ized in a self-describing XML document annotated with
well-defined common data elements. TMA data exchange
specifications have recently been described by Berman et
al. [11,39]. Adopting these standards should allow for a
seamless integration of public TMA databases. The public
sharing of TMA data following publication of data, similar
to standards developed for expression array data exchange
should facilitate biomedical research. As part of a
National Biospecimens Pilot Project[40], the 11 Prostate
Cancer S.P.O.R.E. groups will adopt these standard and
work with the Cancer Biomedical Informatics Grid
(caBIG) program [41] to ensure that these standards
remain compliant. Future versions of this system will
adopt an ontology system developed in collaboration
with the caBIG program. Currently our vocabulary and
definitions have been more locally defined and will need
to be adjusted as these standards become better defined.
Profiler can be set up at academic institutions that would
like to use this system. Although the system is currently
written for Oracle, the Profiler application can be
deployed to Open Source Software. Apache Web Server
[42] and Tomcat Engine [43] are currently Open Source
Software. All front end codes for Profiler application can
modify to support to Open Source. There are several Open
Source databases such as MySQL [44] or PostgreSQL [45]
that can be integrated with Profiler application with small
modification of JDBC drivers and Java codes. We are cur-
rently looking for an Open Source Image application to
support TMA images. The Profiler system is available to all
academic intuitions using a standard academic licensing
agreement. This procedure is intended to make the system
widely available and is required by our institutions based
on their established intellectual properties policies. Any
interested investigators should contact the corresponding
author to begin the licensing procedure. Groups using a
different database system (e.g., MySQL) may need to
modify the database scripts and perform additional test-
ing. But in general both the code and the relational data-
base schema are highly portable.
Conclusion
In summary, we have described a process to deal with
TMA experiments using a system called Profiler. The TMA
module of Profiler allows for a secure and reliable way to
evaluate and store TMA images over the Internet. The
database allows for integration of other types of dataset
including clinical and pathology data. The system has
been extensively used for the evaluation of biomarkers
and has proven to be reliable and stable at two Compre-
hensive Cancer Centers. This system is freely available to
academic intuitions through a standard licensing agree-
ment.
Methods
TMA construction
TMA technology allows for the placement of 400–800 0.6
mm diameter tissue samples into a single standard tissue
block[1]. High-density TMA are assembled using either
the manual or automated tissue puncher/array. These
instruments consist of thin-walled stainless steel needles
with an inner diameter of approximately 600 µm and
stylet used to transfer and empty the needle contents. The
assembly is held in an X-Y position guide that is manually
adjusted by digital micrometers. Small biopsies are
retrieved from selected regions of donor tissue and are
precisely arrayed in a new paraffin block (Figure 1c). The
study pathologist selects the area of interest used for place-
ment into the TMAs by circling the area on a standard
H&E glass slide representative of the tissue block.
All experiments that can be performed on standard tissue
sections can also be performed using TMAs (Figure 1c).
Therefore DNA, RNA or protein expression can be evalu-
ated on TMAs by using FISH, in situ hybridization, immu-
nohistochemistry or immunoflourescene.
In situ protein expression: human versus automated 
evaluation
The evaluation of tissue samples have been traditionally
performed by pathologists using microscopy. Usually
staining intensity is scored with a 4 nominal point scale
(negative, weak positive, moderate positive, strong posi-
tive) and the stained area is scored as a percentage value.
However, the human eye, even if trained, cannot detect
subtle differences in staining intensity on a continuous
scale, in particular at very low and very high levels of the
scale. Moreover the nominal categories are highly subjec-
tive and inter- intra-observer agreement is poor. In con-
trast, quantitative detection of immunostaining provides
continuous measures ensuring reproducibility. The con-
tinuous quantitative measurements obtained by semi-
automatic evaluation can better detect the information of
the investigated target, allowing the detection of subsets
of tumors not seen using human/pathologist based assess-Page 7 of 11
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flourescene[7].
Currently, there are no fully automated methods of evalu-
ating protein expression by immunohistochemisity with-
out the concurrent evaluation by a pathologist.
Depending on how carefully the area of interest is circled
the typical 0.6 mm diameter core may or may not contain
this sample. Thus the targeted (pre-transfer diagnosis)
sample is often but not always what ends up on the TMA
recipient block. Further complicating this is the possibility
that as one cuts deeper into the TMA block, the lesion of
interest due to tissue heterogeneity may not be consistent
throughout. Therefore, it is critical along every step of the
evaluation process that a pathologist or someone trained
at interpreting histologic samples confirms the diagnosis
of the sample.
Profiler system (version 3.0)
Profiler is a Java-based web application designed to pro-
vide flexible access to TMA data consisting of scanned
images and the associated evaluations. Profiler was ini-
tially developed through NCI funding as part of a supple-
ment to the Prostate Cancer S.P.O.R.E. at the University of
Michigan in 2001. Version 3.0 has been set up at the Uni-
versity of Michigan Comprehensive Cancer Center and at
the Dana Farber Harvard Cancer Center.
A fundamental principle for the Profiler system is compli-
ance with current regulatory guidelines to ensure patient
data security and confidentiality. In addition to general
guidelines such as those established by Health Insurance
Portability and Accountability Act (HIPAA), standards for
sharing and transmitting data have been implemented by
such groups as the Cooperative Prostate Cancer Tissue
Resource (CPCTR)[46] to ensure compliance with the
Cancer Biomedical Informatics Grid[41], an initiative of
the NCI.
Profiler is implemented as a Java application running on
top of the Apache web server and of the Tomcat Java
engine. This architecture, based on open standards, is reli-
able, well-tested and highly scalable, and allows the users
to connect to the system using any Java-compliant web
browser rather than requiring ad-hoc client programs. It
also allows the developers to take advantage of the secu-
rity features of modern Web tools, including SSL secure
sockets which provide strong encryption of the data pass-
ing between the client and the server.
The heart of the Profiler system is the Java middleware
that implements the "business logic" of the application
and that manages the entire user session, using Java Beans
to track the various parameters of the session. Java Server
Pages (JSP) functions are used to generate HTML pages
that are specific for the user, on the basis of his/her access
permissions, and of the tool he/she is using within the
application. The customized user interface presents the
user with only the menus and tools he/she is allowed to
see for the intended task, thus reducing confusion and
preventing entry errors.
The Oracle relational database represents the foundation
of the system, offering high performance and a high level
of security. Oracle also supports the full suite of JDBC,
SQL and XML tools to link to data in other databases. Sup-
port of XML facilitates the interchange of data with collab-
orators and allows us to provide links, where appropriate,
to other source-of-truth databases (the clinical LIS, for
example), rather than duplicate the data in our databases.
Data that is stored locally includes TMA histospot infor-
mation, pathology evaluation results, and TMA image
information.
Image handling is fully integrated within the TMA Profiler
application. TMA images are stored in JPEG format and
are displayed in the interface page by a specialized Java
image viewer that allows the user to zoom into the image
or to move it in real time. The viewer is optimized to effi-
ciently download images from the image server, and to
work at different resolution levels according to the
amount of data received.
An example of how the TMA Profiler system is currently
being used can be seen at in a website recently set up for
public viewing of the expression of JAGGED1 in prostate
cancer[30].
The Profiler System runs on two dual-processor servers,
each with one Gigabyte of RAM memory. The first server,
running the Microsoft Windows 2000 operating system,
hosts the imaging server based on the Webslide Server
package (Bacus Labs, Lombard, IL). The second server,
running the Red Hat ® Linux operating system, hosts the
web server (Apache), Jakarta Tomcat, the Oracle database
and the JSP code for the entire application.
TMA data structure
The Profiler system consists of modules for the organiza-
tion and analysis of molecular data. The TMA module was
developed from a previously described Microsoft Access
relational database[10]. The current version 3.0 of Profiler
utilizes a centralized relational database performing auto-
matic queries, which can be accessed over the Internet.
Profiler utilizes external modular data structures as a
means to link TMA pathology or clinical data. When new
data such as kayotype data is added into the database, it is
stored in the form of a module. These modules give Pro-
filer the ability to incorporate relational information
without having to restructure the system. Each modulePage 8 of 11
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the time the data is accessed. Figure 1a shows a schematic
representation of how each module is used in accordance
with the relational database. To incorporate a new mod-
ule, a linkage key must be included in the module to serve
as a means to relate all the appropriate information. Data
queries can only be executed on a permission basis. Dif-
ferent datasets, while related, are kept separate from non-
collaborating researchers. The Profiler system is adaptable
to the changing research demands on a project basis.
In the initial iteration of this database, only prostate organ
specific data was tracked[10]. As the system expanded to
other users studying other organ systems, we developed
look up tables specific to these organ sites such as lung,
breast, pancreatic, head and neck, and the hematopoietic
system. A specific list of possible diagnoses and grading
parameters are kept separate for each organ type into
look-up tables. The organ specific or project specific
parameters can be added dynamically so that the system
does not have to be adjusted to accommodate the
changes. Each tissue specific list can be updated while
only displaying chosen fields during the evaluation. Dur-
ing the evaluation stage, the user interface alters its diag-
nostic parameters based on the organ tissue of the TMA
core. As an example, the diagnostic parameters would
change based on each TMA core of a multi-tumor array.
Image acquisition
Digital images are acquired for each histospot of each
TMA experiment. The reason is twofold. On one hand,
TMA digital images complete the information stored for
each experiment. On the other hand, the availability of
good quality digital images allows for user-friendly TMA
sample evaluations on a screen.
During the initial development of the Profiler system, we
selected the BLISS Imaging system of the Bacus Laboratory
Inc. Slide Scanner (BLISS®) (Bacus Laboratory Inc., Lom-
bard, IL). It is a semi-automated system to acquire high
resolution images, as previously described [10]. The
images are captured in JPEG format and are uploaded
onto the Profiler server via FTP (file transfer protocol).
Once the images are uploaded, the server is setup to dis-
play the images according to the TMA specifications. Each
TMA file is constructed using a data file containing infor-
mation about each tissue sample in the array.
External imaging analysis systems
Profiler V3.0 has the capability to integrate data from
external image analysis systems into its database. For
example, we set up an integration module for the Auto-
mated Cellular Imaging System (ACIS II) from Clarient
Chromavision Medical Systems (San Juan Capitstrano,
CA). This system works on quantitative evaluation of pro-
tein expression on bright field. It creates a panoramic
overview of the sample, acquires single spot images and
then performs quantitative evaluation. Images can be
exported from the Chromavision system as JPG, TIFF, or
GIF files. We are also developing import filters for data
generated from the Automated Quantitative Analysis
(AQUA) system (HistoRX Inc., New Haven, CT). AQUA is
a fluorescent based imaging system, which is capable of
quantitating sub-cellular localization of protein expres-
sion [7,26].
Web-based TMA evaluation interface
After a TMA experiment has been completed (Figure 1c)
and the TMA slide is scanned using one of the imaging sys-
tems described above, the pathologist reviewer enters a
folder with a collection of all images associated with the
given study. Once the review process begins, the reviewer
can either select images to review or will more routinely
go from the first image and be presented all of the cap-
tured images for that study (Figure 1d). Each TMA core
image is viewed one at a time. The reviewer can annotate
the tissue, assigning the appropriate diagnosis, staining
intensity, and other organ specific parameters. The presen-
tation of which parameters are required will vary from
study to study and therefore are entirely flexible. A typical
interface for the TMA evaluation process is presented in
Figure 1d. Each high resolution TMA core image is dis-
played with the option of zooming in and out and pan-
ning over the image, simulating the functionality of
looking at a slide under the microscope. A corresponding
hematoxylin and eosin stained (H&E) image can be
viewed to assist in the evaluation. Diagnostic parameters
for each sample are stored and the next spot is displayed.
A small legend map of the array can be displayed showing
the status of each core whether it has been evaluated or
flagged for review (Figure 1d, lower right). Evaluations
can be completed over multiple sessions with the legend
map indicating which cores have yet to be reviewed. The
legend map is used to navigate to any particular core in
the array. Completed evaluations are time stamped and
associated with a particular evaluator. A demonstration of
this interface is available for evaluation[31].
Data privacy and security
Once a TMA slide is scanned, TMA core images can be
viewed online using Profiler's evaluation interface. To log
in, each user must enter their username and password at
Profiler's home page in order to access their slides. User-
names and passwords are created only after a user has reg-
istered an account. TMAs displayed on Profiler can be
evaluated from any computer with an Internet connec-
tion.
In the United States, the integration of Clinical and
Pathology data from external databases must be compli-Page 9 of 11
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191)[47]. In brief, we use a research code provided by the
designated curators of each of the clinical databases. Each
clinical and pathology database requires its own Institu-
tional Review Board (IRB) Protocol number prior to
incorporation into Profiler. This is in agreement with the
IRB policies and procedures at both of the sponsoring
institutions. According to HIPAA, Sec. 164.514(a)-(c), the
Privacy Rule permits a covered entity to de-identify pro-
tected health information (PHI). The unique, de-identi-
fied patient ID therefore can not use any 18 PHI data
elements specified by the Privacy Rule. The resulting de-
identified patient ID is then the only master ID entered
into the central Profiler database in conjunction with
associated clinical, pathologic, genomic, and other sam-
ple related data. The de-identified patient ID is also used
for identifying biological samples during all aspects of
experimentation, data collection, and data viewing by
researchers. Re-linkage of de-identified consortium
patient ID to actual patient identifiers is manually possi-
ble only by specific representative of each research group
with manual control of the local linkage list and under
guidance of their home IRB policies.
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